Literature DB >> 20512041

Altered intestinal function precedes the appearance of bacterial DNA in serum and ascites in patients with cirrhosis: a pilot study.

Ulrich Thalheimer1, Fosca De Iorio, Franco Capra, Maria del Mar Lleo, Valeria Zuliani, Valentina Ghidini, Maria Carla Tafi, Greta Caburlotto, Micol Gennari, Andrew K Burroughs, Italo Vantini.   

Abstract

OBJECTIVES: Bacterial translocation seems to precede the occurrence of overt bacterial infection in patients with cirrhosis. The presence of bacterial DNA in blood and ascites correlates with bacterial translocation and is frequent in patients with advanced cirrhosis without overt infection. Our aim was to search for bacterial DNA in patients with cirrhosis both with and without ascites, and to study its correlation with abnormal intestinal motility or permeability and the presence of bacterial overgrowth.
METHODS: Blood and ascites samples were obtained on day 1, and blood samples were taken twice a day for the following 3 days. Bacterial DNA was assayed by polymerase chain reaction using universal primers for rRNA 16 s. Oro-caecal transit time and bacterial overgrowth were assessed with Lactulose H(2) breath testing. Intestinal permeability was assessed by determining urinary lactulose and mannitol excretion with high performance liquid chromatography.
RESULTS: We studied seven patients (six were male, age range was 42-78 years). Aetiology was alcohol in four, HCV in two, HBV in one; ascites was present in four and Child-Pugh grade was A in four and B in three. All patients had increased intestinal permeability, six had decreased transit time and one had bacterial overgrowth. In only one patient (with ascites), polymerase chain reaction was positive for bacterial DNA both in ascites and serum for all 4 days on which samples were taken.
CONCLUSION: Increased intestinal permeability and abnormal motility were frequent without evidence of bacterial translocation in cirrhosis even without ascites. They are likely to be facilitators for bacterial translocation and thus precede it.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20512041     DOI: 10.1097/MEG.0b013e32833b4b03

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  19 in total

1.  Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications.

Authors:  Georgios I Tsiaoussis; Stelios F Assimakopoulos; Athanassios C Tsamandas; Christos K Triantos; Konstantinos C Thomopoulos
Journal:  World J Hepatol       Date:  2015-08-18

2.  The role of the gut microbiota in nonalcoholic fatty liver disease.

Authors:  Ahmed Abu-Shanab; Eamonn M M Quigley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-02       Impact factor: 46.802

3.  Fate of pathogenic bacteria in microcosms mimicking human body sites.

Authors:  Francesco Castellani; Valentina Ghidini; Maria Carla Tafi; Marzia Boaretti; Maria M Lleo
Journal:  Microb Ecol       Date:  2013-05-09       Impact factor: 4.552

4.  Presence of multiple bacterial markers in clinical samples might be useful for presumptive diagnosis of infection in cirrhotic patients with culture-negative reports.

Authors:  M Boaretti; F Castellani; M Merli; C Lucidi; M M Lleo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-01-11       Impact factor: 3.267

5.  Expression of α-Defensins, CD20+ B-lymphocytes, and Intraepithelial CD3+ T-lymphocytes in the Intestinal Mucosa of Patients with Liver Cirrhosis: Emerging Mediators of Intestinal Barrier Function.

Authors:  Georgios I Tsiaoussis; Eleni C Papaioannou; Eleni P Kourea; Stelios F Assimakopoulos; Georgios I Theocharis; Michalis Petropoulos; Vasileios I Theopistos; Georgia G Diamantopoulou; Zoi Lygerou; Iris Spiliopoulou; Konstantinos C Thomopoulos
Journal:  Dig Dis Sci       Date:  2018-06-07       Impact factor: 3.199

Review 6.  Microbial translocation across the GI tract.

Authors:  Jason M Brenchley; Daniel C Douek
Journal:  Annu Rev Immunol       Date:  2012-01-03       Impact factor: 28.527

7.  Effect of Liver Cirrhosis on the Pharmacokinetics, Metabolism, and Tolerability of Daridorexant, A Novel Dual Orexin Receptor Antagonist.

Authors:  Benjamin Berger; Jasper Dingemanse; Giancarlo Sabattini; Stéphane Delahaye; Urs Duthaler; Clemens Muehlan; Stephan Krähenbühl
Journal:  Clin Pharmacokinet       Date:  2021-05-18       Impact factor: 6.447

Review 8.  Leaky gut and the liver: a role for bacterial translocation in nonalcoholic steatohepatitis.

Authors:  Yaron Ilan
Journal:  World J Gastroenterol       Date:  2012-06-07       Impact factor: 5.742

Review 9.  Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis.

Authors:  Valerio Giannelli; Vincenza Di Gregorio; Valerio Iebba; Michela Giusto; Serena Schippa; Manuela Merli; Ulrich Thalheimer
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

10.  Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage Adjustments.

Authors:  Fiona V Bϋdingen; Daniel Gonzalez; Amelia N Tucker; Hartmut Derendorf
Journal:  Ther Adv Infect Dis       Date:  2014-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.